-
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda2020 Blood article Biochemistry, Genetics and Molecular Biology Amyloidosis: Diagnosis, Treatment, Outcomes
Raymond L. Comenzo, Efstathios Kastritis, Giovanni O. Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, +27 more
15citations -
Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
Andreas Burchert, Susanne Saußele, Stephan Metzelder, Andreas Hochhaus, Norbert Gattermann, Martina Margrit Crysandt, +27 more
13citations -
Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF2025 Blood article Biochemistry, Genetics and Molecular Biology Glycosylation and Glycoproteins Research Open access
Ciara Byrne, Soracha E. Ward, Jamie M. O’Sullivan, Alain Chion, Patrícia das Dores Lopes, Bogdan Baci, +13 more
10citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations -
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study
Tim H. Brümmendorf, Patrick G. Medd, Raphael Koch, Stephan Stilgenbauer, Shringi Sharma, Yun He, +4 more
8citations